血清标志物半乳糖凝集素-3与心房颤动射频消融术后复发的相关性分析  

Analysis of the correlation between serum biomarker Galectin-3 and the recurrence of atrial fibrillation after radiofrequency ablation

作　　者：隗祎[1] 丁金花 郭馨竹 李霞玲 梁卓[1] 张涛[1] 赵华[1] 王云龙[1] 韩智红[1] 王楠[2] 任学军[1] WEI Yi;DING Jinhua;GUO Xinzhu;LI Xialing;LIANG Zhuo;ZHANG Tao;ZHAO Hua;WANG Yunlong;HAN Zhihong;WANG Nan;REN Xuejun(Department of Cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart,Lung and Blood Vessel Diseases,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所心内科3A病房,100029 [2]天津科技大学

出　　处：《心肺血管病杂志》2019年第5期469-472,483,共5页Journal of Cardiovascular and Pulmonary Diseases

基　　金：心血管疾病精准医学北京实验室-心血管疾病临床资源及样本库的队列研究(PXM2018_014226_000013)

摘　　要：目的:该研究旨在揭示血清标志物半乳糖凝集素-3(Gal-3)在心房颤动患者中的表达情况,并探讨基础血清Gal-3水平预测心房颤动射频消融术后复发率的价值。方法:连续入选就诊于北京安贞医院因非瓣膜性心房颤动行心房颤动射频消融术的患者共152例,其中阵发性心房颤动组110例(72.4%),持续性心房颤动组42例(27.6%)。入院后手术前经深静脉采集血液样本冻存,应用酶联免疫吸附试验法(ELISA)测定基础血清Gal-3水平,同时采集基线临床、实验室资料,建立样本库。对心房颤动射频消融术后患者进行前瞻性临床随访,判断射频消融术后复发情况并记录。结果:基础血清Gal-3水平在阵发性/持续性心房颤动中差异无统计学意义[7.11(9.06,41.60)vs.8.88(3.14,53.12)μg/L,P=0.582]。随访时间为(340.9±145.8)d,心房颤动复发共42例(27.8%),其中持续性心房颤动组13例(31.0%),阵发性心房颤动组29例(26.6%)。心房颤动复发组血清Gal-3水平高于维持窦律者[38.52(3.65,220.73)vs.4.00(0.22,13.69)μg/L,P=0.001]。多因素回归分析显示,血清Gal-3是心房颤动射频消融术后复发的危险因素(OR=1.009,95%CI:1.005~1.014,P<0.001)。结论:心房颤动复发组血清Gal-3水平高于维持窦律者,可作为预测心房颤动射频消融术后复发的危险因素,帮助临床医生筛选更适合接受心房颤动射频消融手术的患者并使其从手术中获益。Objective:This study is sought to investigate the expression of serum Gal-3 concentration in the AF cohort,and to explore the value of Serum Gal-3 concentration in predicting the clinical outcomes in patients with AF undergoing catheter ablation.Methods:152 consecutive non-vavular AF patients admitted to the third cardiovascular department of Beijing Anzhen Hospital undergoing catheter ablation were included,paroxysmal AF in 110 cases(72.4%),42 cases of persistent AF in 38 cases(27.6%).After admission,Blood samples were collected from deep vein for analysis of serum Gal-3,measured by Enzyme linked immune-sorbent assay(ELISA).Pre-ablation clinical and laboratory data were also recorded,and then creating a sample database.AF patients were followed after ablation for 1 year or more,AF recurrence was recorded.Results:Serum Gal-3[7.11(9.06,41.60)vs.8.88(3.14,53.12)μg/L,P=0.582]concentration have no significant difference between paroxysmal and persistent AF patients.Prospective follow-up time was(340.9±145.8)days,there were a total of 42(27.8%)AF recurrence patients.Among them,13 were persistent AF(31.0%)and 29 were paroxysmal AF(26.6%).Patients with AF recurrence had higher serum Gal-3 concentration than those without recurrence[38.52(3.65,220.73)vs.4.00(0.22,13.69)μg/L,P=0.001].Multivariate regression analysis demonstrated that serum Gal-3(OR=1.009,95%CI:1.005-1.014,P<0.001)concentrations were independent predictors of recurrence after catheter ablation.Conclusions:Patients with AF recurrence had higher serum Gal-3 concentration than those without recurrence.Serum Gal-3 concentration can independently predict AF recurrence after ablation,which Help clinicians choose patients who are more suitable for radiofrequency ablation of atrial fibrillation and benefit more from the surgery.

关 键 词：心房颤动 半乳糖凝集素-3 心房纤维化 射频消融 

分 类 号：R54[医药卫生—心血管疾病]